MolNFT v1 · #122928 · protein
The X-ray structure of inhibitor bound to jcv helicase
5J47 · Large T antigen: “The X-ray structure of inhibitor bound to jcv helicase”. X-ray diffraction, 2 ligands (6JJ, ZN), 3 pockets (best druggability 0.63). MolNFT v1 #122928 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 5J47
- Type
- protein
- Length
- 360 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Large T antigen
- EC
- 3.6.4.-
- UniProt
- P03072
- Ligands
- 6JJ, ZN
- Pockets
- 3 · best druggability 0.63
Structure
x-ray diffraction · 1 distinct chain · 58% helix, 8% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Large T antigen (EC 3.6.4.-) | protein | 360 | 58% helix, 8% strand | P03072 |
Ligands and binding sites
- 6JJ · 6-(2-phenoxyphenyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole · ligand · chains A
- ZN · Zinc ion · metal · chains A
- MES · 2-(N-morpholino)-ethanesulfonic acid · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 399 | 0.63 | 0.78 | 48 | empty |
| 2 | 96 | 0.52 | 0.82 | 13 | empty |
| 3 | 94 | 0.43 | 0.78 | 17 | 6JJ |
Compared structures
- 5J47 · The X-ray structure of Inhibitor Bound to JCV Helicase · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P03072
- Elsewhere: RCSB PDB 5J47 · PDBe 5J47 · UniProt P03072
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.